FRACTIONATED REIRRADIATION OF RECURRENT IDH WILDTYPE GLIOBLASTOMA: HIGHER REIRRADIAITON DOSE AND SAFETY

被引：0
|
作者：
Lecompte, Michael [1 ]
Vuppala, Neil [2 ]
Reyes, Juan [3 ]
Page, Brandi [1 ]
Croog, Victoria [1 ]
Huang, Ellen [1 ]
Redmond, Kristin [1 ]
Kleinberg, Lawrence [1 ]
机构：
[1] Johns Hopkins Sch Med, Baltimore, MD USA
[2] Alabama Coll Osteopath Med, Dothan, AL USA
[3] Johns Hopkins Univ, Baltimore, MD USA
来源：
NEURO-ONCOLOGY | 2024年 / 26卷
关键词：
D O I：
10.1093/neuonc/noae165.0301
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
RADT-17
引用
收藏
页数：2
相关论文
共 44 条
  • [31] NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA - TRIAL IN PROGRESS
    Bagley, Stephen
    Polley, Mei-Yin
    Kotecha, Rupesh
    Brem, Steven
    Tolakanahalli, Ranjini
    Iwamoto, Fabio
    Gilbert, Mark
    Won, Minhee
    Mehta, Minesh
    NEURO-ONCOLOGY, 2022, 24 : 64 - 64
  • [32] Chemotherapy plus concomitant low-dose fractionated radiotherapy as second-line treatment for recurrent or progressive glioblastoma after temozolomide-based chemoradiation: A pilot study.
    D'Agostino, G. R.
    Diletto, B.
    Manfrida, S.
    Mangiola, A.
    Chiesa, S.
    De Filippo, L.
    Frascino, V.
    Micciche', F.
    Anile, C.
    Balducci, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Low Dose Fractionated Radiation Therapy as a ChemoPotentiator of Salvage Temozolomide (TMZ) for Recurrent Anaplastic Astrocytoma (AA) and Glioblastoma Multiforme (GBM): A Single-Arm Phase I/II Trial
    Lin, T. A.
    Ke, S.
    Hu, C.
    Assadi, R. K.
    Huang, J.
    Kleinberg, L. R.
    Mukherjee, D.
    Weingart, J.
    Holdhoff, M.
    Grossman, S.
    Redmond, K. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : S85 - S85
  • [34] REGORAFENIB IN COMBINATION WITH TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT-METHYLATED, IDH WILDTYPE GLIOBLASTOMA: A PHASE I DOSE-FINDING STUDY (REGOMA-2, EUDRA CT N° 2021-001604-15)
    Padovan, M.
    De Salvo, G.
    Cerretti, G.
    Krengli, M.
    Caccese, M.
    Maccari, M.
    Farina, M.
    Bergo, E.
    Zabeo, C.
    Grosso, D.
    Caumo, F.
    Coppola, M.
    D'Avolio, A.
    Zagonel, V.
    Lombardi, G.
    NEURO-ONCOLOGY, 2023, 25
  • [35] A Safety and Efficacy Comparison of High Dose Definitive (> 70 Gy) Versus Postoperative Reirradiation Using Intensity Modulated Radiation Therapy (IMRT) in Recurrent or Second Primary Head and Neck Cancer
    Zakem, S. J.
    Koyfman, S.
    Ward, M. C.
    Nwizu, T.
    Reddy, C. A.
    Lamarre, E.
    Scharpf, J.
    Burkey, B. B.
    Greskovich, J. F., Jr.
    Adelstein, D. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E342 - E342
  • [36] EFFICACY AND SAFETY OF METFORMIN PLUS LOW-DOSE TEMOZOLOMIDE IN PATIENTS WITH RECURRENT OR REFRACTORY GLIOBLASTOMA: A RANDOMIZED, PROSPECTIVE, MULTICENTER, DOUBLE-BLIND, CONTROLLED, PHASE 2 TRIAL
    Yoon, Wan Soo
    Chang, Jong Hee
    Kim, Jeong Hoon
    Kim, Yu Jung
    Jung, Tae Young
    Yoo, Heon
    Kim, Se-Hyuk
    Do-Hyun Nam
    Kim, Tae Min
    Kim, Se Hoon
    Park, Sung Hye
    Lee, Youn Soo
    Kim, Hyeon Woo
    Hong, Yong-Kil
    Yang, Seung Ho
    NEURO-ONCOLOGY, 2023, 25
  • [37] TARGETED THERAPY MATCHED TO GENOMIC ALTERATIONS (BRAFV600E, NTRK, FGFR, ROS1, PIK3CA, PTEN) IN PATIENTS WITH RECURRENT IDH WILDTYPE GLIOBLASTOMA: A REAL-LIFE COHORT ANALYSIS FROM VENETO INSTITUTE OF ONCOLOGY, PADUA (ITALY)
    Padovan, M.
    De Toni, C.
    Maccari, M.
    Bosio, A.
    Cerretti, G.
    Caccese, M.
    Corra, M.
    Vizzaccaro, S.
    Cestonaro, I.
    Pittaro, A.
    Guerriero, A.
    Coppola, M.
    Lombardi, G.
    NEURO-ONCOLOGY, 2023, 25
  • [38] The clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in newly diagnosed and recurrent IDH-wildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study.
    Lombardi, Giuseppe
    Giunco, Silvia
    Cavallin, Francesco
    Angelini, Chiara
    Caccese, Mario
    Cerretti, Giulia
    De Bonis, Pasquale
    De Rossi, Anita
    Zagonel, Vittorina
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study)
    Wan-Soo Yoon
    Jong Hee Chang
    Jeong Hoon Kim
    Yu Jung Kim
    Tae-Young Jung
    Heon Yoo
    Se-Hyuk Kim
    Young-Cho Ko
    Do-Hyun Nam
    Tae Min Kim
    Se Hoon Kim
    Sung-Hae Park
    Youn Soo Lee
    Hyeon Woo Yim
    Yong-Kil Hong
    Seung Ho Yang
    Discover Oncology, 14
  • [40] Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study)
    Yoon, Wan-Soo
    Chang, Jong Hee
    Kim, Jeong Hoon
    Kim, Yu Jung
    Jung, Tae-Young
    Yoo, Heon
    Kim, Se-Hyuk
    Ko, Young-Cho
    Nam, Do-Hyun
    Kim, Tae Min
    Kim, Se Hoon
    Park, Sung-Hae
    Lee, Youn Soo
    Yim, Hyeon Woo
    Hong, Yong-Kil
    Yang, Seung Ho
    DISCOVER ONCOLOGY, 2023, 14 (01)
12345